elaidic acid-cytarabine
a 5'-elaidic acid (C18:1, unsaturated fatty acid) ester of cytarabine
Networked: 1
relevant articles (1 outcomes,
0 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Related Diseases
1. | Hematologic Neoplasms (Hematological Malignancy)
|
2. | Neoplasms (Cancer)
06/15/1999
- " P-4055 induced partial or complete tumor regression of the lung carcinoma, as well as of all three malignant melanomas. " 06/15/1999
- " In two of the melanomas the activity was highly superior to that of cytarabine, and both P-4055 and cytarabine were, in general, more effective than several clinically established drugs previously tested in the same tumor models. " 06/15/1999
- " xenograft models, the effects of maximum tolerated doses of P-4055 and cytarabine, given in four weekly cycles of daily bolus i.v. injections for 5 subsequent days, against seven tumors (three melanomas, one lung adenocarcinoma, one breast cancer, and two osteogenic sarcomas) were investigated. " 06/15/1999
- " The antineoplastic efficacy of P-4055, a 5'-elaidic acid (C18:1, unsaturated fatty acid) ester of cytarabine, a nucleoside antimetabolite frequently used in the treatment of hematological malignancies, was examined in several in vivo models for human cancer. "
|
3. | Meningeal Carcinomatosis
|
4. | Osteosarcoma (Osteogenic Sarcoma)
|
5. | Melanoma (Melanoma, Malignant)
06/15/1999
- " P-4055 induced partial or complete tumor regression of the lung carcinoma, as well as of all three malignant melanomas. " 06/15/1999
- " In two of the melanomas the activity was highly superior to that of cytarabine, and both P-4055 and cytarabine were, in general, more effective than several clinically established drugs previously tested in the same tumor models. " 06/15/1999
- " xenograft models, the effects of maximum tolerated doses of P-4055 and cytarabine, given in four weekly cycles of daily bolus i.v. injections for 5 subsequent days, against seven tumors (three melanomas, one lung adenocarcinoma, one breast cancer, and two osteogenic sarcomas) were investigated. "
|
|
Related Drugs and Biologics
Related Therapies and Procedures